Literature DB >> 6734360

Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer.

U Metzger, J Meier, G Uhlschmid, H Weihe.   

Abstract

To evaluate the influence of inhibitors of prostaglandin synthesis on the incidence of DMH-induced colon cancer, 90 male Sprague-Dawley rats were randomly assigned to: indomethacin 20 mg per liter drinking water, meclofenamate 50 mg per liter drinking water, or normal drinking water (control group). Dimethylhydrazine was given by weekly subcutaneous injections (20 mg/kg body weight) during the first 20 weeks. Thirty-two weeks after the start of treatment and carcinogen exposure, the animals were killed and examined for the number, size, location, and spread of intestinal tumors. Colon cancer incidence was significantly lower in animals receiving indomethacin (56 per cent) compared with the control group (88 per cent) and with the meclofenamate group (90 per cent) (P less than 0.005). The corresponding figures for tumors in the small intestine were 31, 46, and 35 per cent, respectively. The tumors in indomethacin-treated animals did not differ in number, size, location, or spread from tumors of the other groups, suggesting that indomethacin might influence the carcinogenic process itself, rather than the natural course of the established disease. We conclude that indomethacin significantly reduces the incidence of large-bowel cancer in this animal model and that this observation may have some potential for future chemopreventive studies in human high-risk groups (e.g. ulcerative colitis, familial polyposis).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734360     DOI: 10.1007/BF02553001

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  13 in total

1.  Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production.

Authors:  X Shi; M Ding; Z Dong; F Chen; J Ye; S Wang; S S Leonard; V Castranova; V Vallyathan
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

Review 2.  Aspirin, NSAIDs, and digestive tract cancers.

Authors:  M J Thun
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

3.  Effect of aspirin and NSAIDs on colorectal adenomas. Protective effect may be spurious.

Authors:  S V Lo; H U Perry; R Lyons
Journal:  BMJ       Date:  1993-09-18

4.  Aspirin and risk of fatal colon cancer.

Authors:  G P Morgan; J G Williams
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

Review 5.  Can nonsteroidal anti-inflammatory drugs be recommended to prevent colon cancer in high risk elderly patients?

Authors:  M I Koutsos; S J Shiff; B Rigas
Journal:  Drugs Aging       Date:  1995-06       Impact factor: 3.923

6.  Inhibition of activator protein 1 activity and neoplastic transformation by aspirin.

Authors:  Z Dong; C Huang; R E Brown; W Y Ma
Journal:  J Biol Chem       Date:  1997-04-11       Impact factor: 5.157

7.  Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2.

Authors:  S Pugh; G A Thomas
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

Review 8.  Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer.

Authors:  D Turner; H J Berkel
Journal:  CMAJ       Date:  1993-09-01       Impact factor: 8.262

9.  Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.

Authors:  C Gustafson-Svärd; I Lilja; O Hallböök; R Sjödahl
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

10.  Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme.

Authors:  R F Logan; J Little; P G Hawtin; J D Hardcastle
Journal:  BMJ       Date:  1993-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.